查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087632

結核病治療市場：2026-2032年全球市場預測（依結核病類型、給藥途徑、藥物類別、年齡層、通路和最終用戶分類）

Tuberculosis Drugs Market by Tuberculosis Type, Route Of Administration, Drug Class, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，結核病治療市場將成長至 31.4 億美元，複合年成長率為 5.03%。

主要市場統計數據
基準年 2025 22.3億美元
預計年份：2026年 23.4億美元
預測年份 2032 31.4億美元
複合年成長率 (%) 5.03%

結核病仍然是世界上最致命的感染疾病之一，結核病治療在全球感染疾病控制中繼續發揮核心作用。根據世界衛生組織（世衛組織）估計，到2023年，預計將有1080萬人患有結核病，125萬人死於該病，這凸顯了對一線結核病治療藥物、抗藥性結核病治療方案、兒童結核病產品以及能夠提高患者用藥依從性的給藥模式的持續需求。

商業性優先事項受兩種並行現實的影響：一方面，大多數藥物敏感性結核病仍採用以利福黴素、異煙肼、Pyrazinamide和乙胺丁醇為主的成熟療法進行治療；另一方面，耐多藥結核病和利福平耐藥結核病則需要採用新型的全口服聯合治療，例如包含貝達喹啉、Linezolid的對於製藥公司、全球衛生採購負責人和公共部門採購人員而言，商機在於穩定的供應、差異化的製劑、品質保證、藥物安全監測以及符合世衛組織結核病治療指南，而非高昂的價格。

將重塑結核病治療藥物市場格局的變革

結核病治療格局正從長期注射療法轉向短期全口服、以病人為中心的治療方案。世界衛生組織建議對合格的多重抗藥性或利福平抗藥性結核病患者採用6個月的BPaLM方案和基於BPaL的治療方案，這顯著改變了採購預期，提高了貝達喹啉、普瑞托馬尼、利奈唑Linezolid和Fluoroquinolones藥物持續供應的戰略重要性。

人工智慧對結核病藥物研發和治療的影響。

人工智慧（AI）正透過提高篩檢效率、加速目標族群識別和加強藥物安全監測，開始影響結核病治療生態系統。世界衛生組織已認可電腦輔助胸部X光相片檢測在特定情況下可作為篩檢工具，透過將其與可靠的診斷和藥物取得途徑相結合，將有助於更及時地識別需要確診檢測的人群，並啟動適當的結核病治療。

結核病治療藥物的區域需求趨勢

亞太地區是結核病治療藥物最重要的需求中心。這是因為世界衛生組織已將印度、印尼、中國、菲律賓、巴基斯坦、孟加拉和其他區域市場列為全球結核病發病率的主要貢獻者。光是印度就佔全球結核病負擔的約四分之一，因此，在該地區推行公共採購、國內生產、固定劑量組合藥物和短期治療方案是確保藥物可近性的關鍵。同時，亞太地區各結核病負擔較重的區域都在優先發展診斷系統、促進私部門參與、加強兒童結核病防治以及開發抗藥性結核病治療體系。

結核病治療藥物策略組別的發展趨勢

東協是結核病治療藥物供應商的重要策略區域。印尼、菲律賓、越南、緬甸和泰國面臨沉重的結核病負擔，同時各國也不斷擴大結核病控制項目，並增加捐助者支持的採購。該地區的市場動態支持品質有保證的學名藥、兒童製劑、固定劑量組合藥物、短期治療方案以及分散式醫療模式，這些模式能夠確保患者無論身處都市區、農村或島嶼地區都能完成治療。

全國結核病治療藥物的商業機會

在美國，疾病管制與預防中心（CDC）報告稱，2023年共發生9633例結核病病例，這使得人們越來越需要快速獲得針對活動性結核病的標靶治療、潛伏性結核病感染的治療以及抗藥性結核病的專業知識。雖然加拿大和澳洲的結核病發病率仍然很低，但對於移民群體、原住民社區和專門的公共衛生計畫而言，穩定的藥品供應至關重要。墨西哥和巴西仍然是拉丁美洲的主要市場，由於都市區感染、社會因素以及公共部門治療計畫的存在，兩國對品質有保證的一線治療和用藥依從性支持的需求持續存在。

對結核病治療產業領導者的建議

製藥業領導者應優先考慮利福平、異煙肼、Pyrazinamide、乙胺丁醇、利福噴丁、貝達喹啉、Linezolid和莫西沙星的供應穩定性，因為斷貨會直接影響治療的完成和抗藥性的預防。各公司應使其產品組合符合世界衛生組織指南、國家基本藥物目錄、藥品安全監測要求以及全球藥品基金（GDF）的品質要求，以提高其參與公共採購的合格。

實證調查方法

本執行摘要基於經核實的公共衛生和監管證據，包括來自世界衛生組織全球結核病規劃、國家結核病監測機構的數據、同行評審的臨床試驗證據、FDA 和 EMA 產品資訊、更新的治療夥伴關係以及檢驗相關資訊來源（如遏制結核病夥伴關係全球藥品基金）。

策略結論

結核病治療市場呈現出持續的疾病負擔、對抗藥性結核病日益成長的擔憂，以及向更短療程、全口服給藥和以患者為中心的治療模式轉變的趨勢。雖然結核病高發生率的需求仍然最高，但高所得國家在治療潛伏性感染疾病、引入創新療法、監測藥物安全性和製定監管標準方面也發揮著重要作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 結核病治療市場：依結核病類型分類

  • 活動性肺結核
    • 藥物敏感性結核病
      • 肺結核
      • 肺外結核病
    • 抗藥性結核病
      • 耐多藥結核病
      • 廣泛傳播的抗藥性結核病
  • 潛伏性結核感染

第8章 結核病治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第9章 結核病治療市場：依藥物類別分類

  • 基於利法黴素
  • Fluoroquinolones
  • Aminoglycosides抗生素
  • Oxazolidinone系列
  • 硝基咪唑類藥物

第10章 結核病治療市場：依年齡層別分類

  • 兒童
  • 成人

第11章 結核病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 結核病治療市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 結核病治療中心
  • 居家照護環境

第13章 結核病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 結核病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 結核病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Johnson & Johnson Services, Inc.
  • Hikma Pharmaceuticals PLC
  • Sanofi SA
  • Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Viatris Inc.
  • FarmaVision Healthcare
  • SiNi Pharma Pvt Ltd
  • AstraZeneca PLC
  • Cadila Pharmaceuticals Limited
  • Fresenius SE & Co. KGaA
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-03252A5F9277

The Tuberculosis Drugs Market is projected to grow by USD 3.14 billion at a CAGR of 5.03% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.23 billion
Estimated Year [2026] USD 2.34 billion
Forecast Year [2032] USD 3.14 billion
CAGR (%) 5.03%

Tuberculosis drugs remain central to global infectious disease control as TB continues to rank among the world's deadliest communicable diseases. The World Health Organization (WHO) reported that an estimated 10.8 million people developed TB in 2023 and 1.25 million people died from the disease, underscoring sustained need for first-line tuberculosis treatment, drug-resistant TB regimens, pediatric TB formulations, and adherence-enabling delivery models.

Commercial priorities are being shaped by two concurrent realities: most drug-susceptible TB is still treated with established rifamycin-, isoniazid-, pyrazinamide-, and ethambutol-based regimens, while multidrug-resistant TB and rifampicin-resistant TB require newer all-oral options such as bedaquiline-, pretomanid-, linezolid-, and moxifloxacin-containing combinations. For pharmaceutical manufacturers, global health procurers, and public-sector buyers, opportunity is tied less to premium pricing and more to reliable supply, differentiated formulations, quality assurance, pharmacovigilance, and alignment with WHO tuberculosis treatment guidelines.

Market Shifts Reshaping TB Therapeutics

The tuberculosis drugs landscape is shifting from long, injectable-heavy treatment pathways toward shorter, all-oral, patient-centered regimens. WHO recommendations for six-month BPaLM and BPaL-based regimens for eligible multidrug-resistant or rifampicin-resistant TB patients have materially changed procurement expectations by increasing the strategic relevance of bedaquiline, pretomanid, linezolid, and fluoroquinolone supply continuity.

At the same time, TB prevention and latent tuberculosis infection treatment are gaining policy attention in low-incidence markets and among high-risk populations. Shorter preventive therapy regimens using rifapentine and isoniazid are improving completion rates versus longer isoniazid monotherapy, creating demand for formulations and distribution models that fit community-based care, migrant health programs, HIV services, occupational screening initiatives, and contact-tracing programs.

AI Impact on TB Drug Discovery and Care

Artificial intelligence is beginning to influence the tuberculosis drugs ecosystem by improving screening efficiency, accelerating target identification, and strengthening pharmacovigilance. WHO has recognized computer-aided detection for chest radiography as a screening tool in defined settings, which can expand timely identification of people who require confirmatory testing and appropriate TB therapy initiation when linked to reliable diagnostic and medicine access pathways.

For manufacturers and research organizations, AI-enabled molecular modeling, literature mining, resistance prediction, safety-signal detection, and trial-site optimization can reduce friction in TB drug development. However, measurable commercial and clinical impact depends on validation, regulatory acceptance, representative datasets, and integration with laboratory confirmation, because AI cannot substitute for microbiological diagnosis, drug-susceptibility testing, or evidence from controlled clinical trials.

Regional Demand Patterns for TB Drugs

Asia-Pacific is the most consequential demand center for tuberculosis drugs because WHO identifies India, Indonesia, China, the Philippines, Pakistan, Bangladesh, and other regional markets among the major contributors to global TB incidence. India alone accounts for roughly one-quarter of the global TB burden, making public procurement, domestic manufacturing, fixed-dose combinations, and shorter treatment adoption central to regional access. In parallel, high-burden Asia-Pacific settings are prioritizing diagnostic scale-up, private-sector engagement, pediatric TB care, and drug-resistant TB treatment capacity.

North America and Europe have lower TB incidence but remain important for latent tuberculosis infection management, migrant health programs, specialty drug-resistant TB care, strict regulatory oversight, and pharmacovigilance requirements. Latin America, led by Brazil, Peru, and Mexico, shows sustained need for public-sector treatment supply, adherence programs, and urban TB control. The Middle East's tuberculosis drug demand is influenced by expatriate and migrant worker screening, cross-border mobility, and centralized hospital procurement, while Africa remains a high-priority region because TB-HIV coinfection, diagnostic gaps, financing constraints, and medicine availability continue to shape demand for affordable first-line drugs and scalable drug-resistant TB regimens.

Strategic Group-Level TB Drug Signals

ASEAN is strategically important for tuberculosis drug suppliers because Indonesia, the Philippines, Vietnam, Myanmar, and Thailand combine high disease burden with expanding national TB programs and donor-supported procurement. The region's market dynamics favor quality-assured generics, pediatric formulations, fixed-dose combinations, shorter regimens, and decentralized care models that support treatment completion across urban, rural, and island geographies.

The GCC is a lower-incidence but operationally important group where expatriate health screening, hospital procurement, and antimicrobial stewardship influence demand for tuberculosis therapeutics. The European Union and G7 markets emphasize regulatory compliance, latent TB management, surveillance-led treatment, and specialty care for drug-resistant disease, while NATO countries also prioritize infectious disease surveillance, medical readiness, and resilient medicine supply chains. BRICS is the most consequential group for volume and policy influence because India, China, Russia, Brazil, and South Africa collectively include major TB and drug-resistant TB burdens, significant domestic manufacturing capacity, and large public-sector purchasing systems.

Country-Level TB Drug Opportunities

In the United States, the CDC reported 9,633 TB cases in 2023, reinforcing demand for targeted active TB treatment, latent tuberculosis infection therapy, and rapid access to drug-resistant TB expertise. Canada and Australia maintain low-incidence profiles but require steady supply for foreign-born populations, Indigenous communities, and specialized public health programs. Mexico and Brazil remain key Latin American markets because urban transmission, social determinants, and public-sector treatment programs sustain demand for quality-assured first-line medicines and adherence support.

Across Europe, the United Kingdom, Germany, France, Italy, and Spain focus on surveillance-led treatment, migrant screening, latent TB strategies, and guideline-compliant medicine access, while Russia remains particularly significant for multidrug-resistant TB and rifampicin-resistant TB management. China and India are decisive volume markets, with India driving the largest global treatment need and China emphasizing scale, surveillance, and domestic production. Japan and South Korea are mature healthcare markets where aging populations, low-to-moderate incidence, hospital-based care, and strong regulatory expectations shape demand for reliable TB therapeutics.

Recommendations for TB Drug Leaders

Industry leaders should prioritize supply resilience for rifampicin, isoniazid, pyrazinamide, ethambutol, rifapentine, bedaquiline, pretomanid, linezolid, and moxifloxacin, because stockouts can directly affect treatment completion and resistance prevention. Companies should align portfolios with WHO guidance, national essential medicines lists, pharmacovigilance expectations, and Global Drug Facility quality requirements to strengthen eligibility for public procurement.

Manufacturers can improve competitiveness by investing in heat-stable formulations, pediatric dispersible products, fixed-dose combinations, shorter-regimen packaging, robust quality systems, and country-specific access partnerships. R&D leaders should focus on safer sterilizing regimens, resistance-sparing combinations, long-acting or adherence-supporting approaches, and biomarkers that shorten trials while maintaining rigorous evidence standards.

Evidence-Based Research Methodology

This executive summary is built from verified public-health and regulatory evidence, including WHO Global TB Programme data, national TB surveillance agencies, peer-reviewed clinical trial evidence, FDA and EMA product information, treatment guideline updates, and procurement-oriented sources such as the Stop TB Partnership Global Drug Facility.

The methodology applies triangulation across epidemiology, treatment algorithms, country burden, procurement practices, regulatory pathways, resistance patterns, and pipeline signals. Insights are validated through cross-comparison of incidence trends, drug-resistance burden, policy adoption, therapy availability, and guideline evolution to ensure that conclusions reflect documented market realities rather than speculative estimates.

Strategic Conclusion

The tuberculosis drugs market is defined by persistent disease burden, rising attention to drug-resistant TB, and the transition toward shorter, all-oral, patient-centered regimens. Demand remains highest where TB incidence is concentrated, but high-income markets also play an important role in latent tuberculosis infection treatment, innovation adoption, pharmacovigilance, and regulatory standard-setting.

Organizations that combine reliable supply, WHO-aligned portfolios, evidence-based innovation, quality-assured manufacturing, and access-focused partnerships will be best positioned to serve public health needs while building durable relevance in tuberculosis therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tuberculosis Drugs Market, by Tuberculosis Type

  • 7.1. Active Tuberculosis
    • 7.1.1. Drug-Susceptible Tuberculosis
      • 7.1.1.1. Pulmonary Tuberculosis
      • 7.1.1.2. Extrapulmonary Tuberculosis
    • 7.1.2. Drug-Resistant Tuberculosis
      • 7.1.2.1. Multidrug-Resistant Tuberculosis
      • 7.1.2.2. Extensively Drug-Resistant Tuberculosis
  • 7.2. Latent Tuberculosis Infection

8. Tuberculosis Drugs Market, by Route Of Administration

  • 8.1. Injectable
  • 8.2. Oral

9. Tuberculosis Drugs Market, by Drug Class

  • 9.1. Rifamycins
  • 9.2. Fluoroquinolones
  • 9.3. Aminoglycosides
  • 9.4. Oxazolidinones
  • 9.5. Nitroimidazoles

10. Tuberculosis Drugs Market, by Age Group

  • 10.1. Pediatrics
  • 10.2. Adults

11. Tuberculosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Tuberculosis Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics
  • 12.3. Tuberculosis Treatment Centers
  • 12.4. Homecare Settings

13. Tuberculosis Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Tuberculosis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tuberculosis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Johnson & Johnson Services, Inc.
  • 17.2. Hikma Pharmaceuticals PLC
  • 17.3. Sanofi S.A.
  • 17.4. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • 17.5. Cipla Limited
  • 17.6. GlaxoSmithKline PLC
  • 17.7. Eli Lilly and Company
  • 17.8. Viatris Inc.
  • 17.9. FarmaVision Healthcare
  • 17.10. SiNi Pharma Pvt Ltd
  • 17.11. AstraZeneca PLC
  • 17.12. Cadila Pharmaceuticals Limited
  • 17.13. Fresenius SE & Co. KGaA
  • 17.14. Lupin Limited
  • 17.15. Macleods Pharmaceuticals Ltd.
  • 17.16. Merck & Co., Inc.
  • 17.17. Otsuka Pharmaceutical Co., Ltd.
  • 17.18. Pfizer Inc.
  • 17.19. Sandoz International GmbH
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG-SUSCEPTIBLE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EXTRAPULMONARY TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIDRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LATENT TUBERCULOSIS INFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RIFAMYCINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RIFAMYCINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RIFAMYCINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-SUSCEPTIBLE TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG-RESISTANT TUBERCULOSIS, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA TUBERCULOSIS DRUGS MA